Peptide and Anticoagulant Drugs Market
  • Published Date: Aug-2021
  • |
  • 180 Pages
  • |
  • Report ID: PH0007

Peptide and Anticoagulant Drugs Market

The Peptide and Anticoagulant Drugs market is expected to grow from USD 1.51 billion in 2019 to USD 2.11 million by 2025 at a CAGR of 5% from 2020 to 2026.

  • Report Description
  • Table of Content
  • Segmentation
  • Companies

Peptides drugs are probably to have a large range of applications in treating many diseases to Illustrate pathology, cancer, cardiovascular, diabetes, and coagulation disorders. Peptides are essentially molecules that are universally called proteins, whose major functions are recognized based on the amino acid size and sequence.

The global Peptide and Anticoagulant Drugs market is segregated on the basis of Type as Hormonal, Antibiotic, Ace Inhibitors, Antifungal, and Other Peptide Drugs. Based on Application the global Peptide and Anticoagulant Drugs market is segmented in Diabetes, Infectious Diseases, Cancer, Osteoporosis, Cardiology, Gynecology, and Other Applications. Based on Low Molecular Weight Heparin Type the global Peptide and Anticoagulant Drugs market is segmented in Enoxaparin Sodium, Heparin Sodium, Fondaparinux, and Dalteparin Sodium.

The global Peptide and Anticoagulant Drugs market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Peptide and Anticoagulant Drugs market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

Competitive Rivalry

Abbott Laboratories, Sanofi S.A., Eli Lilly and Company, Cipla Limited, Biocon Limited, Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd, Cadila Pharmaceuticals, Lupin Limited, Emcure Pharmaceuticals Ltd, and others are among the major players in the global Peptide and Anticoagulant Drugs market. The companies studied in terms of product strategy and various n several growth and expansion strategies to gain a competitive edge in the market. The major players not only follow value chain integration with business operations in multiple stages of the value chain.

The global Peptide and Anticoagulant Drugs market has been segmented as below:

Peptide and Anticoagulant Drugs Market, By Type

  • Hormonal
  • Antibiotic
  • Ace Inhibitors
  • Antifungal
  • Other Peptide Drugs

Peptide and Anticoagulant Drugs Market, By Application

  • Diabetes
  • Infectious Diseases
  • Cancer
  • Osteoporosis
  • Cardiology
  • Gynecology
  • Other Applications

Peptide and Anticoagulant Drugs Market, By Low Molecular Weight Heparin Type

  • Enoxaparin Sodium
  • Heparin Sodium
  • Fondaparinux
  • Dalteparin Sodium

Peptide and Anticoagulant Drugs Market, By Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Peptide and Anticoagulant Drugs Market, By Company

  • Abbott Laboratories
  • Sanofi S.A.
  • Eli Lilly and Company
  • Cipla Limited
  • Biocon Limited
  • Intas Pharmaceuticals Ltd.
  • Sun Pharmaceutical Industries Ltd
  • Cadila Pharmaceuticals
  • Lupin Limited
  • Emcure Pharmaceuticals Ltd
  • Novartis International AG
  • Reddy’s Laboratories Limited
  • Alkem Laboratories Limited

The report covers the below scope:

  • Global Peptide and Anticoagulant Drugs market sizes from 2015 to 2024, along with CAGR for 2018-2024
  • Market size comparison for 2017 vs 2024, with actual data for 2017, estimates for 2018 and forecast from 2019 to 2024
  • Global Peptide and Anticoagulant Drugs market trends, covering comprehensive range of consumer trends & manufacturer trends
  • Value chain analysis covering participants from raw material suppliers to the downstream buyer in the global Peptide and Anticoagulant Drugs market
  • Major market opportunities and challenges in forecast timeframe to be focused
  • Competitive landscape with analysis on competition pattern, portfolio comparisons, development trends and strategic management
  • Comprehensive company profiles of the key industry players

The years considered for the study are as follows:

  • Base year - 2018
  • Estimated year - 2019
  • Projected year - 2020
  • Forecast period - 2021 to 2025

Report Scope:

The global Peptide and Anticoagulant Drugs market report scope includes detailed study covering underlying factors influencing the industry trends. The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies. The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Peptide and Anticoagulant Drugs market share. Major industry players with significant revenue share include Abbott Laboratories, Sanofi S.A., Eli Lilly and Company, Cipla Limited, Biocon Limited, Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd, Cadila Pharmaceuticals, Lupin Limited, Emcure Pharmaceuticals Ltd, and others.

Why to Buy this Report:

  • Gain detailed insights on the Peptide and Anticoagulant Drugs industry trends
  • Find complete analysis on the market status
  • Identify the Peptide and Anticoagulant Drugs market opportunities and growth segments
  • Analyse competitive dynamics by evaluating business segments & product portfolios
  • Facilitate strategy planning and industry dynamics to enhance decision making

Target Audience:

The report targeted towards the existing players in the industry is as follows:

  • Market Manufacturers/Service Providers
  • Market Wholesale/Traders
  • Investment and Financial Institutions

Free and Paid Customization based on the requirement

Report Content

 

  1. Introduction

            1.1 Key Insights

            1.2 Report Overview

            1.3 Markets Covered

            1.4 Stakeholders

  1. Research Methodology

            2.1 Research Scope

            2.2 Market Research Process

            2.3 Research Data Analysis

                        2.4.1 Secondary Research

                        2.4.2 Primary Research

                        2.4.3 Models for Estimation

            2.5 Market Size Estimation

                        2.5.1 Bottom-Up Approach - Segmental Market Analysis

                        2.5.2 Top-Down Approach - Parent Market Analysis

  1. Executive Summary
  2. Market Overview

            4.1 Introduction

                        4.2.1 Drivers

                        4.2.2 Restraints

                        4.2.3 Opportunities

                        4.2.4 Challenges

            4.2 Porter''s Five Force Analysis

  1. Peptide and Anticoagulant Drugs Market, By Type

            5.1 Introduction

            5.2 Hormonal

                        5.2.1 Market Overview

                        5.2.2 Market Size and Forecast

            5.3 Antibiotic

                        5.3.1 Market Overview

                        5.3.2 Market Size and Forecast

            5.4 Ace Inhibitors

                        5.4.1 Market Overview

                        5.4.2 Market Size and Forecast

            5.5 Antifungal

                        5.5.1 Market Overview

                        5.5.2 Market Size and Forecast

            5.6 Other Peptide Drugs

                        5.6.1 Market Overview

                        5.6.2 Market Size and Forecast

  1. Peptide and Anticoagulant Drugs Market, By Application

            6.1 Introduction

            6.2 Diabetes

                        6.2.1 Market Overview

                        6.2.2 Market Size and Forecast

            6.3 Infectious Diseases

                        6.3.1 Market Overview

                        6.3.2 Market Size and Forecast

            6.4 Cancer

                        6.4.1 Market Overview

                        6.4.2 Market Size and Forecast

            6.5 Osteoporosis

                        6.5.1 Market Overview

                        6.5.2 Market Size and Forecast

            6.6 Cardiology

                        6.6.1 Market Overview

                        6.6.2 Market Size and Forecast

            6.7 Gynecology

                        6.7.1 Market Overview

                        6.7.2 Market Size and Forecast

            6.8 Other Applications

                        6.8.1 Market Overview

                        6.8.2 Market Size and Forecast

  1. Peptide and Anticoagulant Drugs Market, By Low Molecular Weight Heparin Type

            7.1 Introduction

            7.2 Enoxaparin Sodium

                        7.2.1 Market Overview

                        7.2.2 Market Size and Forecast

            7.3 Heparin Sodium

                        7.3.1 Market Overview

                        7.3.2 Market Size and Forecast

            7.4 Fondaparinux

                        7.4.1 Market Overview

                        7.4.2 Market Size and Forecast

            7.5 Dalteparin Sodium

                        7.5.1 Market Overview

                        7.5.2 Market Size and Forecast

  1. Peptide and Anticoagulant Drugs Market, By Geography

            8.1 Introduction

            8.2 North America

                        8.2.1 North America Peptide and Anticoagulant Drugs, By Type

                        8.2.2 North America Peptide and Anticoagulant Drugs, By Application

                        8.2.3 North America Peptide and Anticoagulant Drugs, By Low Molecular Weight Heparin Type

            8.3 Europe

                        8.3.1 Europe Peptide and Anticoagulant Drugs, By Type

                        8.3.2 Europe Peptide and Anticoagulant Drugs, By Application

                        8.3.3 Europe Peptide and Anticoagulant Drugs, By Low Molecular Weight Heparin Type

            8.4 Asia-Pacific

                        8.4.1 Asia-Pacific Peptide and Anticoagulant Drugs, By Type

                        8.4.2 Asia-Pacific Peptide and Anticoagulant Drugs, By Application

                        8.4.3 Asia-Pacific Peptide and Anticoagulant Drugs, By Low Molecular Weight Heparin Type

            8.5 Rest of the World

                        8.5.1 Rest of the World Peptide and Anticoagulant Drugs, By Type

                        8.5.2 Rest of the World Peptide and Anticoagulant Drugs, By Application

                        8.5.3 Rest of the World Peptide and Anticoagulant Drugs, By Low Molecular Weight Heparin Type

  1. Competitive Insights

            9.1 Key Insights

            9.2 Company Market Share Analysis

            9.3 Strategic Outlook

                        9.3.1 Mergers & Acquisitions

                        9.3.2 New Product Development

                        9.3.3 Portfolio/Production Capacity Expansions

                        9.3.4 Joint Ventures, Collaborations, Partnerships & Agreements

                        9.3.5 Others

  1. Company Profiles
  • Abbott Laboratories
  • Sanofi S.A.
  • Eli Lilly and Company
  • Cipla Limited
  • Biocon Limited
  • Intas Pharmaceuticals Ltd.
  • Sun Pharmaceutical Industries Ltd
  • Cadila Pharmaceuticals
  • Lupin Limited
  • Emcure Pharmaceuticals Ltd
  • Novartis International AG
  • Reddy’s Laboratories Limited
  • Alkem Laboratories Limited

The global Peptide and Anticoagulant Drugs market has been segmented as below:

Peptide and Anticoagulant Drugs Market, By Type

  • Hormonal
  • Antibiotic
  • Ace Inhibitors
  • Antifungal
  • Other Peptide Drugs

Peptide and Anticoagulant Drugs Market, By Application

  • Diabetes
  • Infectious Diseases
  • Cancer
  • Osteoporosis
  • Cardiology
  • Gynecology
  • Other Applications

Peptide and Anticoagulant Drugs Market, By Low Molecular Weight Heparin Type

  • Enoxaparin Sodium
  • Heparin Sodium
  • Fondaparinux
  • Dalteparin Sodium

Peptide and Anticoagulant Drugs Market, By Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Peptide and Anticoagulant Drugs Market, By Company

  • Abbott Laboratories
  • Sanofi S.A.
  • Eli Lilly and Company
  • Cipla Limited
  • Biocon Limited
  • Intas Pharmaceuticals Ltd.
  • Sun Pharmaceutical Industries Ltd
  • Cadila Pharmaceuticals
  • Lupin Limited
  • Emcure Pharmaceuticals Ltd
  • Novartis International AG
  • Reddy’s Laboratories Limited
  • Alkem Laboratories Limited

License Options

  • Single 1500 USD
  • Multiple 3000 USD